Healthcare

UAE scientists harness AI to discover potential blood cancer drug

UAE-based researchers at Insilico Medicine used AI to identify potential PROTAC drugs for blood cancers. The company says its approach could significantly shorten early drug-selection timelines.

Researchers at Insilico Medicine, which has scientists based in Masdar City, Abu Dhabi, used artificial intelligence to identify a class of drugs called PROTACs as potential treatments for blood cancers, including some leukaemias and lymphomas. The company’s AI platforms helped identify disease-related target proteins and support selection of promising compounds.

The reported approach is intended to shorten the early drug-discovery process. Insilico said its AI-driven method can reduce drug-selection timelines to approximately 12 to 18 months, compared with roughly 2.5 to 4 years using conventional approaches.

The work illustrates how AI is being applied beyond medical imaging and hospital administration, particularly in target identification and molecule selection. The candidate drugs remain part of a development process and are not described as approved treatments.

The development matters for the UAE’s biotechnology strategy because it links local scientific activity and investment infrastructure with computational drug discovery. It also demonstrates a practical application of AI in oncology research, where identifying effective targets and compounds is often a lengthy and expensive process.

Original source: The National

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI